Iparomlimab and Tuvonralimab Combined With 2 or 4 Cycles of Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC

Clinical trial NCT07129161 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07129161
Sponsor: Sun Yat-sen University
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Carcinoma, Non-Small-Cell Lung

Start date: 2025-08-01
Primary completion: 2026-10-01
Enrollment: 66

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.